THE FDA Approval of ONC201 (DORDAVIPRONE, NOW MODEYSO™) is the first and only treatment for recurrent H3 K27M-MUTANT Diffuse Midline Glioma

Written By Jeannine Gallagher
Jeannine Gallagher
Previous

PNOC FOUNDATION LAUNCHES $50 MILLION "LOSE NO CHILD" CAMPAIGN TO TRANSFORM THE FUTURE OF TREATMENT FOR KIDS WITH BRAIN CANCER